Trial Profile
Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Oct 2014 New trial record